MT1002 / Shaanxi Micot Technology - LARVOL DELTA

A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Shaanxi Micot Technology Limited Company

New P2 trial • Acute Coronary Syndrome • Cardiovascular

MT1002 Phase II Study in ACS Patients With PCI (clinicaltrials.gov) - P2 | N=6 | Terminated | Sponsor: Shaanxi Micot Technology Limited Company | Suspended ➔ Terminated; The study was decided to be terminated due to commercial considerations,（not the safety issues of the product）.

Trial termination • Acute Coronary Syndrome • Cardiovascular

MT1002 Phase II Study in ACS Patients With PCI (clinicaltrials.gov) - P2 | N=6 | Suspended | Sponsor: Shaanxi Micot Technology Limited Company | N=20 ➔ 6 | Recruiting ➔ Suspended | Trial primary completion date: Mar 2023 ➔ Jul 2023

Enrollment change • Trial primary completion date • Trial suspension • Acute Coronary Syndrome • Cardiovascular

Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics (clinicaltrials.gov) - P1 | N=2 | Terminated | Sponsor: Shaanxi Micot Technology Limited Company | N=24 ➔ 2 | Trial completion date: Apr 2023 ➔ Jun 2022 | Recruiting ➔ Terminated | Trial primary completion date: Mar 2023 ➔ Jun 2022; Strategic decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Coronary Syndrome • Cardiovascular • Renal Disease

MT1002 Phase II Study in ACS Patients With PCI (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Shaanxi Micot Technology Limited Company | Trial completion date: Jan 2023 ➔ May 2023 | Trial primary completion date: Dec 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Cardiovascular

MT1002 Phase II Study in ACS Patients With PCI (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Shaanxi Micot Technology Limited Company | Trial primary completion date: Sep 2022 ➔ Dec 2022

Trial primary completion date • Acute Coronary Syndrome • Cardiovascular

Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Shaanxi Micot Technology Limited Company | Trial completion date: Dec 2022 ➔ Apr 2023 | Trial primary completion date: Sep 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Cardiovascular • Renal Disease

Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Shaanxi Micot Technology Limited Company

New P1 trial • Acute Coronary Syndrome • Cardiovascular • Renal Disease

MT1002 Phase II Study in ACS Patients With PCI (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Shaanxi Micot Technology Limited Company | Trial completion date: Jul 2022 ➔ Dec 2022 | Trial primary completion date: May 2022 ➔ Sep 2022

Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Cardiovascular

MT1002 Phase II Study in ACS Patients With PCI (clinicaltrials.gov) - P2; N=20; Recruiting; Sponsor: Shaanxi Micot Technology Limited Company; Active, not recruiting ➔ Recruiting; Trial completion date: Oct 2021 ➔ Jul 2022; Trial primary completion date: Aug 2021 ➔ May 2022

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Cardiovascular

MT1002 Phase II Study in ACS Patients With PCI (clinicaltrials.gov) - P2; N=20; Active, not recruiting; Sponsor: Shaanxi Micot Technology Limited Company

Clinical • New P2 trial • Acute Coronary Syndrome • Cardiovascular

Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection (clinicaltrials.gov) - P1; N=30; Completed; Sponsor: Shaanxi Micot Technology Limited Company; Active, not recruiting ➔ Completed

Clinical • Trial completion